Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

3221results about How to "Reduce degradation" patented technology

Heparin barrier coating for controlled drug release

ActiveUS20050004663A1Reduce frictional forceReduce forceSuture equipmentsStentsCompound (substance)Antioxidant
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.

Conversational computing via conversational virtual machine

A conversational computing system that provides a universal coordinated multi-modal conversational user interface (CUI) 10 across a plurality of conversationally aware applications (11) (i.e., applications that “speak” conversational protocols) and conventional applications (12). The conversationally aware applications (11) communicate with a conversational kernel (14) via conversational application APIs (13). The conversational kernel 14 controls the dialog across applications and devices (local and networked) on the basis of their registered conversational capabilities and requirements and provides a unified conversational user interface and conversational services and behaviors. The conversational computing system may be built on top of a conventional operating system and APIs (15) and conventional device hardware (16). The conversational kernel (14) handles all I / O processing and controls conversational engines (18). The conversational kernel (14) converts voice requests into queries and converts outputs and results into spoken messages using conversational engines (18) and conversational arguments (17). The conversational application API (13) conveys all the information for the conversational kernel (14) to transform queries into application calls and conversely convert output into speech, appropriately sorted before being provided to the user.

Methods, compositions and systems for local delivery of drugs

Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.

Method for modification of radiotherapy treatment delivery

The present invention provides a novel method of contoured-anatomy dose repositioning (CADR) as a means to automatically reposition a patient to better recover the planned dose distribution without reoptimize the treatment plan. Specifically, CADR utilizes planning CT images, the planned dose distribution, and on-line images for repositioning dose distribution on a given day. Contours are also placed upon the images using manual, automatic, template-based, or other techniques. CADR then optimizes the rigid-body repositioning of the patient so that the daily dose distribution closely matches the planned dose distribution. The present invention also provides a method of multiple-margin optimization with daily selection (MMODS) to improve radiation delivery without reoptimization. During the initial optimization procedure, plans are optimized for several margins of various contours (e.g., tight, medium, loose, etc.), or with different objectives (e.g., aggressive treatment, sensitive structure sparing, etc.). Similarly, if multiple patient image sets are available, plans can be optimized for the different anatomical layouts, either using current information, or accumulated information regarding the superposition of organ locations in the combination of images. A user can then choose in real time from a variety of optimized plans, generally with different margins, during the treatment process, and thereby compensate for a recognized change in size or position of the tumor or neighboring tissue.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products